155748-81-5

Basic information

• Product Name: (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine
• Synonyms: 3-benzyl-3-azabicyclo[3.1.0]hexan-6-amine
• CAS NO: 155748-81-5
• Molecular Formula: C₁₂H₁₆N₂
• Molecular Weight: 188
• Mol File: 155748-81-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 280℃
• Flash Point: 112℃
• Appearance: /
• Density: 1.145
• Vapor Pressure: 0.004mmHg at 25°C
• Refractive Index: 1.615
• CAS DataBase Reference: (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine(CAS DataBase Reference)
• NIST Chemistry Reference: (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine(155748-81-5)
• EPA Substance Registry System: (3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine(155748-81-5)

Safety Data

• Hazardous Substances Data: 155748-81-5(Hazardous Substances Data)

Usage

General Description

"(3-Benzyl-3-azabicyclo[3.1.0]hex-6-yl)amine" is a chemical compound that belongs to the class of organic compounds known as benzylic amines. These are organic compounds containing an amine group attached directly to a benzyl group. In this case, the structure of this compound includes a benzyl group attached to a 3-azabicyclo[3.1.0]hex-6-yl ring structure. The exact properties, such as its physical state, melting point, and boiling point, may vary depending on the other substituents present in the molecule. Specific data is limited, as it is a less commonly studied or used compound. The uses and potential effects or hazards of this particular chemical compound will mostly depend on its exact formulation and on the conditions of its use.

InChI:InChI=1/C12H16N2/c13-12-10-7-14(8-11(10)12)6-9-4-2-1-3-5-9/h1-5,10-12H,6-8,13H2

Upstream product

• 323575-35-5 3-benzyl-6-nitro-3-azabicyclo [3.1.0]hexane 
• 1631-26-1 1-benzyl-1H-pyrrole-2,5-dione 
• 914937-12-5 3-benzyl-6-nitro-3-azabicyclo[3.1.0]hexane-2,4-dione 

Downstream Products

• 186376-18-1 tert-butyl (3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)carbamate 
• 919119-50-9 Tert-butyl 3-{[(3-benzyl-3-azabicyclo[3.1.0]hex-6-yl)amino]carbonyl}-3,4-dihydroisoquinoline-2(1H)-carboxylate 

Relevant articles and documents

Synthesis, antibacterial activities, mode of action and acute toxicity studies of new oxazolidinone-fluoroquinolone hybrids

To combat bacterial resistance, a series of new oxazolidinone-fluoroquinolone hybrids have been synthesized and characterized. All synthetic hybrids were preliminarily evaluated for their in vitro antibacterial activities against 6 standard strains and 3 clinical isolates. The majority of hybrids displayed excellent activities against Gram-positive bacteria, but limited activities against Gram-negative bacteria. Hybrids OBP-4 and OBP-5 were found to be the most promising compounds. Further, in vitro antibacterial activities, mode of action and acute toxicity in mice of hybrids OBP-4 and OBP-5 were investigated. Hybrids OBP-4 and OBP-5 exhibited potent activities against Gram-positive bacteria, including drug-resistant strains. Correspondingly, studies on the mode of action of hybrids OBP-4 and OBP-5 indicated a strong inhibitory activity on protein synthesis by binding the active site of 50S subunit, but a weak inhibitory action on DNA synthesis. In addition, LD50 values of hybrids OBP-4 and OBP-5 in the acute oral toxicity were larger than 2000 mg/kg, suggesting a good safety profile.

AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE

The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

3,4-DIHYDROISOQUINOLINE COMPOUNDS AS MUSCRINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF RESPIRATORY, URINARY AND GASTROINTESTINAL DISEASES

The present invention generally relates to muscarinic receptor antagonists of formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. Formula (I) wherein Formula (II) represents a nitrogen-containing ring having from 5 to 9 carbon atoms is a bridging group selected from the group consisting of -(CH2)n-, -CH(Q)CH2-, -CH2CH(Q)CH2-, -CH2-O-CH2- or -CH2-NH-CH2-), where n is an integer selected from 0-3 (wherein when n is zero then T represents a direct bond); Y is alkylene, alkenylene, alkynylene or no atom; X is -NH or oxygen.